Teleflex (NYSE:TFX) Raised to Strong-Buy at Zacks Research

Teleflex (NYSE:TFX) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Thursday, Zacks reports.

Several other research analysts also recently commented on TFX. Piper Sandler reaffirmed an “overweight” rating and issued a $169.00 price target (up from $160.00) on shares of Teleflex in a research report on Friday, August 7th. Truist Financial increased their price objective on Teleflex from $143.00 to $150.00 and gave the company a “hold” rating in a research report on Monday, August 10th. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a research note on Monday. UBS Group boosted their target price on shares of Teleflex from $145.00 to $158.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Finally, BMO Capital Markets assumed coverage on shares of Teleflex in a research note on Wednesday, July 8th. They set an “outperform” rating and a $159.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Teleflex currently has an average rating of “Moderate Buy” and an average target price of $152.90.

Teleflex Trading Up 2.0%

Shares of NYSE:TFX opened at $122.44 on Thursday. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.12 and a current ratio of 2.60. The stock’s 50-day moving average is $134.00 and its 200-day moving average is $128.54. The company has a market cap of $5.19 billion, a P/E ratio of -5.26, a P/E/G ratio of 0.80 and a beta of 0.82. Teleflex has a 52-week low of $100.18 and a 52-week high of $145.00.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, August 6th. The medical technology company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.48. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%.The business had revenue of $570.33 million during the quarter, compared to analysts’ expectations of $559.59 million. During the same quarter in the previous year, the firm earned $3.73 EPS. The firm’s revenue was up 28.9% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Equities research analysts predict that Teleflex will post 7.26 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of TFX. BlackRock Inc. acquired a new stake in Teleflex during the second quarter worth $688,537,000. Jupiter Topco LLC acquired a new position in shares of Teleflex in the 2nd quarter valued at $550,456,000. Janus Henderson Group PLC lifted its holdings in shares of Teleflex by 1.1% during the 1st quarter. Janus Henderson Group PLC now owns 4,291,311 shares of the medical technology company’s stock worth $513,281,000 after acquiring an additional 45,199 shares during the period. Geode Capital Management LLC boosted its position in shares of Teleflex by 10.6% during the 4th quarter. Geode Capital Management LLC now owns 985,684 shares of the medical technology company’s stock valued at $120,312,000 after acquiring an additional 94,679 shares in the last quarter. Finally, Irenic Capital Management LP bought a new stake in Teleflex in the first quarter valued at about $104,061,000. 95.62% of the stock is owned by institutional investors.

Teleflex Company Profile

Teleflex Incorporated is a global medical technology company that develops, manufactures and supplies specialty medical devices for hospitals, clinicians and other health care providers. Its products are designed to support procedures in areas including vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgery and urology.

The company’s portfolio includes Arrow branded vascular access and catheter products, airway management devices, regional anesthesia products, surgical instruments, interventional devices and urological products.